Prestige Consumer Healthcare Inc. (NYSE:PBH) Receives Consensus Rating of “Moderate Buy” from Brokerages

Prestige Consumer Healthcare Inc. (NYSE:PBH) has received a consensus recommendation of “Moderate Buy” from the four research firms that are currently covering the firm, MarketBeat Ratings reports. Two investment analysts have rated the stock with a hold rating and two have given a buy rating to the company. The average twelve-month price objective among analysts that have covered the stock in the last year is $85.25.

Several research firms recently weighed in on PBH. Jefferies Financial Group restated a “hold” rating and set a $76.00 target price (up previously from $70.00) on shares of Prestige Consumer Healthcare in a report on Tuesday, September 24th. StockNews.com cut Prestige Consumer Healthcare from a “buy” rating to a “hold” rating in a research note on Tuesday, December 10th. DA Davidson reiterated a “buy” rating and issued a $95.00 target price on shares of Prestige Consumer Healthcare in a research note on Monday, November 11th. Finally, Sidoti downgraded Prestige Consumer Healthcare from a “buy” rating to a “neutral” rating and set a $90.00 target price on the stock. in a report on Monday, December 9th.

Prestige Consumer Healthcare Stock Performance

Prestige Consumer Healthcare stock opened at $82.30 on Monday. The company has a market cap of $4.07 billion, a price-to-earnings ratio of 20.02, a price-to-earnings-growth ratio of 2.32 and a beta of 0.49. Prestige Consumer Healthcare has a 12 month low of $57.95 and a 12 month high of $86.36. The company has a debt-to-equity ratio of 0.61, a current ratio of 3.56 and a quick ratio of 2.10. The stock’s 50-day moving average is $78.12 and its 200-day moving average is $72.54.

Prestige Consumer Healthcare (NYSE:PBH) last posted its quarterly earnings results on Thursday, November 7th. The company reported $1.09 EPS for the quarter, meeting the consensus estimate of $1.09. Prestige Consumer Healthcare had a net margin of 18.54% and a return on equity of 12.23%. The firm had revenue of $283.79 million for the quarter, compared to analyst estimates of $282.09 million. During the same quarter last year, the firm posted $1.07 earnings per share. Prestige Consumer Healthcare’s revenue for the quarter was down .9% compared to the same quarter last year. Equities analysts anticipate that Prestige Consumer Healthcare will post 4.44 earnings per share for the current year.

Insiders Place Their Bets

In other news, CEO Ronald M. Lombardi sold 10,875 shares of the firm’s stock in a transaction that occurred on Tuesday, November 19th. The shares were sold at an average price of $82.60, for a total transaction of $898,275.00. Following the completion of the sale, the chief executive officer now owns 320,952 shares of the company’s stock, valued at approximately $26,510,635.20. This trade represents a 3.28 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, EVP Adel Mekhail sold 9,063 shares of Prestige Consumer Healthcare stock in a transaction on Tuesday, November 12th. The stock was sold at an average price of $82.00, for a total transaction of $743,166.00. Following the completion of the sale, the executive vice president now owns 18,365 shares of the company’s stock, valued at approximately $1,505,930. This trade represents a 33.04 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 38,810 shares of company stock worth $3,187,300 in the last quarter. 1.60% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On Prestige Consumer Healthcare

Large investors have recently modified their holdings of the stock. Martingale Asset Management L P increased its holdings in Prestige Consumer Healthcare by 0.4% in the third quarter. Martingale Asset Management L P now owns 36,971 shares of the company’s stock valued at $2,666,000 after buying an additional 140 shares during the last quarter. Horizon Kinetics Asset Management LLC increased its holdings in shares of Prestige Consumer Healthcare by 4.8% in the 3rd quarter. Horizon Kinetics Asset Management LLC now owns 3,247 shares of the company’s stock valued at $234,000 after acquiring an additional 150 shares during the last quarter. Evergreen Capital Management LLC increased its holdings in shares of Prestige Consumer Healthcare by 5.4% in the 2nd quarter. Evergreen Capital Management LLC now owns 3,143 shares of the company’s stock valued at $216,000 after acquiring an additional 160 shares during the last quarter. Miller Howard Investments Inc. NY raised its position in shares of Prestige Consumer Healthcare by 2.2% during the 2nd quarter. Miller Howard Investments Inc. NY now owns 7,762 shares of the company’s stock valued at $534,000 after acquiring an additional 165 shares in the last quarter. Finally, OLD National Bancorp IN lifted its stake in Prestige Consumer Healthcare by 4.4% during the third quarter. OLD National Bancorp IN now owns 3,974 shares of the company’s stock worth $287,000 after purchasing an additional 168 shares during the last quarter. Institutional investors own 99.95% of the company’s stock.

About Prestige Consumer Healthcare

Prestige Consumer Healthcare Inc, together with its subsidiaries, develops, manufactures, markets, distributes, and sells over-the-counter (OTC) health and personal care products in the United States and internationally. The company operates in two segments, North American OTC Healthcare and International OTC Healthcare.